PNT001

PNT001

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PNT001</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Sponsor</td>
<td>Pinteon Therapeutics</td>
</tr>
<tr>
<td class="label">Start Date</td>
<td>September 2019</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Single ascending dose, placebo-controlled</td>
</tr>
<tr>
<td class="label">Participants</td>
<td>49 healthy adult volunteers</td>
</tr>
<tr>
<td class="label">Dose Range</td>
<td>33 mg to 4,000 mg</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Intravenous infusion</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12-week follow-up</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Start Date</td>
<td>March 2021</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Multiple ascending dose in acute TBI</td>
</tr>
<tr>
<td class="label">Participants</td>
<td>Planned 64, enrolled 1</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Terminated for non-safety reasons</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12-week monitoring</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PNT001</td>
</tr>
<tr>
<td class="label">Target</td>
<td>cis-pT231</td>
</tr>
<tr>
<td class="label">Specificity</td>
<td>Conformation-specific</td>
</tr>
<tr>
<td class

PNT001

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PNT001</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Sponsor</td>
<td>Pinteon Therapeutics</td>
</tr>
<tr>
<td class="label">Start Date</td>
<td>September 2019</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Single ascending dose, placebo-controlled</td>
</tr>
<tr>
<td class="label">Participants</td>
<td>49 healthy adult volunteers</td>
</tr>
<tr>
<td class="label">Dose Range</td>
<td>33 mg to 4,000 mg</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Intravenous infusion</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12-week follow-up</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Start Date</td>
<td>March 2021</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Multiple ascending dose in acute TBI</td>
</tr>
<tr>
<td class="label">Participants</td>
<td>Planned 64, enrolled 1</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Terminated for non-safety reasons</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12-week monitoring</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PNT001</td>
</tr>
<tr>
<td class="label">Target</td>
<td>cis-pT231</td>
</tr>
<tr>
<td class="label">Specificity</td>
<td>Conformation-specific</td>
</tr>
<tr>
<td class="label">Pathological relevance</td>
<td>Early, toxic isoform</td>
</tr>
<tr>
<td class="label">Development status</td>
<td>Inactive</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Folded, aggregated-prone</td>
</tr>
<tr>
<td class="label">Phosphatase sensitivity</td>
<td>Resistant</td>
</tr>
<tr>
<td class="label">Aggregation propensity</td>
<td>High</td>
</tr>
<tr>
<td class="label">Toxicity</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Detectability in AD</td>
<td>Early, prominent</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Registration</td>
<td>NCT03965927</td>
</tr>
<tr>
<td class="label">Start</td>
<td>September 2019</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Randomized, placebo-controlled</td>
</tr>
<tr>
<td class="label">Participants</td>
<td>49 healthy adults</td>
</tr>
<tr>
<td class="label">Dose range</td>
<td>33 mg to 4,000 mg IV</td>
</tr>
<tr>
<td class="label">Primary endpoint</td>
<td>Safety/tolerability</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12 weeks follow-up</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Registration</td>
<td>NCT04708972</td>
</tr>
<tr>
<td class="label">Start</td>
<td>March 2021</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Acute traumatic brain injury</td>
</tr>
<tr>
<td class="label">Planned participants</td>
<td>64</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Terminated (1 patient enrolled)</td>
</tr>
</table>

PNT001 is a monoclonal antibody immunotherapy developed by Pinteon Therapeutics targeting a specific pathological form of tau protein known as cis-phosphorylated tau at threonine 231 (cis-pT231)[@pnt]. This antibody represents a novel approach in tau immunotherapy by specifically targeting the cis conformation of phosphorylated tau, which is resistant to dephosphorylation and degradation, and has been implicated in the pathogenesis of Alzheimer's disease, traumatic brain injury, and potentially Chronic Traumatic Encephalopathy (CTE)[@cis2020].

Unlike conventional anti-tau antibodies that target various phosphorylated epitopes or total tau, PNT001's unique specificity for the cis-pT231 isoform represents a mechanistic distinction that may offer enhanced pathological relevance. The cis conformation of pT231 tau has been shown to be more toxic and aggregation-prone than the trans (normal) phosphorylated form.

Mechanism of Action

Target: cis-pT231 Tau

The therapeutic target of PNT001 is the cis isomer of tau phosphorylated at threonine 231 (cis-pT231)[@cis2020]. This specific post-translational modification is pathologically significant because:

Binding Properties

PNT001 binds specifically to:

• cis-pT231 tau: The pathological cis isomer of tau phosphorylated at threonine 231
• Minimal cross-reactivity: Limited binding to trans-pT231 or other tau phosphorylated forms
• Pathological aggregates: Both soluble oligomers and insoluble fibrils containing cis-pT231

Proposed Therapeutic Mechanism

The mechanism by which PNT001 may exert therapeutic effects includes[@immunotherapy2021]:

Biological Significance of cis-pT231

Discovery and Characterization

The cis-pT231 tau isoform was identified as a pathological driver in tauopathies through extensive research demonstrating[@tauiso2021]:

• Selective toxicity: cis-pT231 is more toxic to neurons than trans-pT231 or non-phosphorylated tau
• Early markers: Detectable in pre-symptomatic AD brains
• Biochemical properties: Seeds aggregation more efficiently than other tau forms
• Therapeutic target potential: Antibodies against cis-pT231 show therapeutic promise in preclinical models

Distribution in Disease

The cis-pT231 isoform is detected in:

• Alzheimer's disease: Prominent in early-stage and moderate-stage cases
• Traumatic brain injury (TBI): Elevated after moderate to severe TBI
• Chronic Traumatic Encephalopathy: Found in CTE-affected brains
• Other tauopathies: Present in PSP, CBD, and FTD cases

Clinical Development

Phase 1: Single Ascending Dose (Healthy Adults)

The Phase 1 trial demonstrated[@pintreon2021]:

• Safety: Well-tolerated across all dose levels with no severe adverse events
• Pharmacokinetics: Dose-linear plasma and CSF concentrations
• Target engagement: For doses ≥900 mg, CSF antibody concentrations exceeded levels needed for tau binding in vitro

Phase 1: Multiple Ascending Dose (Acute TBI)

The TBI study was terminated for business reasons, not safety concerns. The data collected showed antibody reached target concentrations in the single enrolled patient.

Current Status

PNT001's development for Alzheimer's disease and traumatic brain injury is currently inactive, though the scientific foundation for cis-pT231 targeting remains strong and may inform future development programs.

Comparison with Other Tau Immunotherapies

Rationale for cis-pT231 Targeting

Early Pathological Marker

The targeting of cis-pT231 provides potential advantages[@adbiom2022]:

Traumatic Brain Injury Connection

The development for TBI reflects the important link between acute brain injury and chronic neurodegeneration[@tbi2020]:

• Immediate tau pathology: pT231 elevated within hours of TBI
• Chronic effects: Persists months to years post-injury
• CTE connection: TBI is major risk factor for CTE which features tau pathology

Preclinical Evidence

Studies supporting PNT001 development included:

• In vitro binding: High affinity for human brain-derived cis-pT231
• Animal models: Efficacy in tau transgenic mice
• Mechanism validation: Fc-dependent clearance confirmed in preclinical studies

Challenges and Lessons

Development Challenges

The inactivation of PNT001 development reflects broader challenges in tau immunotherapy:

Future Directions

The cis-pT231 target remains scientifically compelling:

• Companion diagnostics for patient selection
• Earlier intervention in disease course
• Combination approaches with other mechanisms

See Also

• [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
• [Tau Protein](/proteins/tau)
• [Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-therapeutics)
• [Traumatic Brain Injury](/diseases/traumatic-brain-injury)
• [Tau Aggregation Mechanisms](/mechanisms/tau-aggregation)
• [Chronic Traumatic Enencephalopathy](/diseases/chronic-traumatic-encephalopathy)

References

The cis-pT231 Discovery: A Paradigm Shift

Historical Context

The identification of cis-phosphorylated tau as a distinct pathological entity represented a significant advance in tau biology. Traditional understanding of tau phosphorylation treated all phosphorylated forms as essentially similar, differing only in the number and location of phosphate groups. The cis-trans isomerization concept introduced a new dimension of complexity.

Key Discovery:
Phosphorylation at threonine 231 creates two distinct conformational isomers:

• trans-pT231: The physiological form that can be dephosphorylated by protein phosphatases
• cis-pT231: A pathological form that is resistant to dephosphorylation and promotes aggregation

Biochemical Properties

The cis conformation differs fundamentally from trans:

Biological Significance

The pathological properties of cis-pT231 make it an attractive therapeutic target:

PNT001 Development History

Pinteon Therapeutics Background

Pinteon Therapeutics was founded to develop antibodies targeting pathological tau conformations. The company's approach centered on the cis-pT231 target, representing a departure from conventional phosphorylation-specific antibodies.

Company Focus:

• Conformation-specific tau antibodies
• Novel therapeutic targets not addressed by other programs
• Biomarker-driven patient selection

Clinical Trial Program

The PNT001 clinical program comprised two sequential Phase I studies:

Study 1: Single Ascending Dose (SAD)

Results:

• All dose levels well-tolerated
• No SAEs related to treatment
• Dose-proportional pharmacokinetics
• CSF antibody levels exceeded target at doses ≥900 mg

The TBI study was terminated for strategic reasons, not safety concerns.

cis-pT231 as a Biomarker

Diagnostic Potential

The cis-pT231 epitope has potential as a biomarker:

Measurement Challenges

Detecting cis-pT231 requires specialized antibodies:

• Specificity: Must distinguish cis from trans conformers
• Sensitivity: Must detect low concentrations in biological fluids
• Standardization: Assays need validation across laboratories

Clinical Development Updates

Safety Profile Analysis

The Phase I trial of PNT001 demonstrated a favorable safety profile across all dose levels studied:

Adverse Events Observed:

• Mostly mild to moderate in severity
• No dose-limiting toxicities identified
• Infusion-related reactions were infrequent and manageable
• No serious adverse events attributed to the antibody

• Dose-proportional exposure in both plasma and CSF
• Half-life supporting monthly or less frequent dosing
• CSF concentrations exceeded target engagement thresholds at higher doses

Target Engagement Evidence

A key finding from Phase I was the demonstration of target engagement:

CSF Biomarker Data:

• At doses ≥900 mg, CSF antibody concentrations reached levels predicted to fully saturate cis-pT231
• Biomarker studies suggested binding of the antibody to its target
• Supported progression to Phase II development planning

Competitive Landscape

Current Tau Immunotherapy Programs

The tau immunotherapy field has evolved since PNT001's development:

Active Programs:

• E2814 (Eisai): MTBR targeting, Phase III
• Bepranemab (UCB): MTBR targeting, Phase II
• JNJ-63733657 (Janssen): p-tau217, Phase II

• Semorinemab (Roche): N-terminal, Phase II negative
• Gosuranemab (Biogen): N-terminal, discontinued
• Tilavonemab (AbbVie): Mid-domain, discontinued
• PNT001 (Pinteon): cis-pT231, inactive

What Made N-terminal Antibodies Fail

Learning from failed programs informs current development:

Conclusion

PNT001 represented an innovative approach to tau immunotherapy, targeting the cis-phosphorylated conformation of tau at threonine 231. This target was grounded in solid science showing cis-pT231 as an early, toxic, aggregation-prone form of tau. The Phase I trial demonstrated safety and target engagement, but development was discontinued for business reasons.

The cis-pT231 target remains scientifically compelling and may be revisited with improved antibody engineering, biomarker-driven patient selection, or combination approaches. The broader field of tau immunotherapy continues to evolve, with MTBR-targeting antibodies now in late-stage development showing more promise than earlier N-terminal approaches.